# Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase

> **NCT00510926** · PHASE2 · COMPLETED · sponsor: **University of Bologna** · enrollment: 80 (—)

## Conditions studied

- Myeloid Leukemia, Chronic, Chronic-Phase

## Interventions

- **DRUG:** Imatinib Mesilate (Glivec)

## Key facts

- **NCT ID:** NCT00510926
- **Lead sponsor:** University of Bologna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** —
- **Final completion:** 2006-11
- **Target enrollment:** 80 (—)
- **Last updated:** 2007-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00510926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00510926, "Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00510926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*